The Maire - EuroChem Case: Three Lessons for Global Business 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Google Halts UK YouTube TV Measurement Service After Legal Action 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
CAMBRIDGE, Mass., May 17, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 2017 UBS Global Healthcare Conference in New York, NY. The presentation is scheduled for 10:30 AM ET on May 24, 2017.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in mainland China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
